Perspectives of bronchial asthma treatment using small interfering RNA
https://doi.org/10.18093/0869-0189-2012-0-4-100-105
Abstract
About the Authors
Zh. A. MironovaRussian Federation
V. I. Тrofimov
Russian Federation
V. V. Vysochinskay
Russian Federation
E. V. Esaulenko
Russian Federation
А. А. Bogdanov
Russian Federation
D. N. Ghorab
Russian Federation
N. A. Кnyazev
Russian Federation
V. V. Zarubaev
Russian Federation
М. V. Dubina
Russian Federation
References
1. Gibeon D.S., Campbell D.A., Menzies-Gow. The systematic assessment of difficult-to-treat asthma: why do it? Clin. Pulm. Med. 2010; 17 (6): 255–259.
2. Федосеев Г.Б., Трофимов В.И., Петрова М.А. Многоликая бронхиальная астма: диагностика, лечение и профилактика. СПб.: Нордмед-Издат; 2011.
3. Чучалин А.Г. Клинические рекомендации по диагностике, лечению и профилактике бронхиальной астмы, одышки: Руководство для врачей. М.: НТЦ КВАНТ; 2005.
4. Лещенко И.В., Лежнина М.Б. Возможности контроля БА на современном уровне. Актуальные проблемы. Consilium Medicum 2009; экстравып. 2–5.
5. Петровский В.Ф., Огородова Л.М. Выбор фармакотерапии тяжелой БА. Пульмонология 2008; 3: 84–89.
6. Чучалин А Г. Бронхиальная астма. М.: Рус. врач; 2001.
7. Barnes P.J. Mechanisms and resistance in glucocorticoid control of inflammation. J. Steroid Biochem. Mol. Biol. 2010; 120: 76–85.
8. Adcock I.M., Barnes P.J. Molecular mechanisms of corticosteroid resistance. Chest 2008; 134: 394–401.
9. Пузырев В.П., Огородова Л.М. Генетика бронхолегочных заболеваний / Под ред. А.Г. Чучалина. М.: Атмосфера; 2010.
10. Миронова Ж.А., Трофимов В.И., Янчина Е.Д., Дубина М.В. Ассоциация вариантов гена бета2-адренорецептора (ADRB2) и бронхиальной астмы. Пробл. клин. мед. 2009, 1 (19): 58–61.
11. Миронова Ж.А., Трофимов В.И., Янчина Е.Д. и др. Мутация С3435Т в гене множественной лекарственной устойчивости MDR1 – фармакогенетический маркер тяжелого течения бронхиальной астмы. Рос. аллергол. журн. 2012; 2: 9–12.
12. Sigurs N., Bjarnason R., Sigurbergsson F. et al. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am. J. Respir. Crit. Care Med. 2000: 161 (5): 1501–1507.
13. Gern J.E., Busse W.W. Relationship of viral infections to wheezing illnesses and asthma. Nature Rev. Immun. 2002; 2 (2): 132–138.
14. Федосеев Г.Б., Трофимов В.И. Бронхиальная астма. СПб.: Нордмед-Издат; 2006.
15. Mahalingam S., Friendland J.S., Heise M.T. Chemokines and viruses: friends or foes?. http//timi.trends.com.2003
16. Message S.D., Laza-Stanca V., Mallia P. et al. Rhinovirusinduced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc. Natl Acad. Sci. USA 2008; 105 (36): 13562–13567.
17. Panickar J., Lakhanpaul M., Lambert P.C. et al. Oral prednisolone for preschool children with acute virus-induced wheezing. N. Engl. J. Med. 2009; 360 (4): 329–338.
18. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am. J. Respir. Crit. Care Med. 2001: 163: 2–6.
19. Lüsebrink J., Schildgen V., Schildgen O. Novel therapies for an old virus: treatment of RSV infections in the 21st Century. Exp. Rev. Anti Infect. Ther. 2009; 7 (9): 1125–1129.
20. Popescu F.D. Antisense- and RNA interference-based therapeutic strategies in allergy. J. Cell. Mol. Med. 2005; 9: 840–853.
21. Janssen L.J. Asthma therapy: how far have we come, why did we fail and where should we go next. Eur. Respir. J. 2009. 33: 11–20.
22. Fire A., Xu S., Montgomery M. K. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998: 391 (6669): 806–811.
23. Dykxhoorn D.M., Novina C.D., Sharp P.A. Killing the messenger: short RNAs that silence gene expression. Nature Rev. Mol. Cell Biol. 2003; 4 (6): 457–467.
24. Cullen B.R. RNAi the natural way. Nature Genet. 2005; 37 (11): 1163–1165.
25. Ambros V. The functions of animal microRNAs. Nature 2004; 431 (7006): 350–355.
26. Winston W.M., Molodowitch C., Hunter C.P. Systemic RNAi in C. elegans requires the putative transmembrane protein SID-1. Science 2002; 295 (5564): 2456–2459.
27. Guo J., Fu Y.C., Becerra C.R. Dissecting role of regulatory factors in NF-kappaB pathway with siRNA. Acta Pharmacol. Sin. 2005; 26: 780–788.
28. Rippmann J.F., Schnapp A., Weith A. et al. Gene silencing with STAT6 specifi c siRNAs blocks eotaxin release in IL-4 / TNFalpha stimulated human epithelial cells. FEBS Lett. 2005; 579: 173–178.
29. Ulanova M., Marcet-Palacios M., Munoz S. et al. Involvement of Sykkinase in TNF-induced nitric oxide production by airway epithelial cells. Biochem. Biophys. Res. Commun. 2006; 351: 431–437.
30. Mattes J., Yang M., Foster P.S. Regulation of microRNA by antagomirs: a new class of pharmacological antagonists for the specifi c regulation of gene function. Am. J. Respir. Cell. Mol. Biol. 2007; 36: 8–12.
31. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy: a review. Virus Genes 2006; 33 (2): 235–252.
32. Акимов В.С., Хаитов М.Р., Файзулоев Е.Б. и др. Подавление репродукции респираторно-синцитиального вируса методом siRNA. Вопр. вирусол. 2007; 2: 8–12.
33. Bitko V., Musiyenko A., Shulyayeva O., Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nature Med. 2005; 11 (1): 50–55.
34. DeVincenzo J., Lambkin-Williams R., Wilkinson T. et al. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc. Natl Acad. Sci USA 2010; 107 (19): 8800–8805.
Review
For citations:
Mironova Zh.A., Тrofimov V.I., Vysochinskay V.V., Esaulenko E.V., Bogdanov А.А., Ghorab D.N., Кnyazev N.A., Zarubaev V.V., Dubina М.V. Perspectives of bronchial asthma treatment using small interfering RNA. PULMONOLOGIYA. 2012;(4):100-105. (In Russ.) https://doi.org/10.18093/0869-0189-2012-0-4-100-105